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Abstract 
We report unexpectedly high efficacy of temsirolimus as third-line treatment in a patient 
with metastatic chromophobe renal cell carcinoma. After failure of two sequentially 
administered tyrosine kinase inhibitors, treatment with temsirolimus resulted in a 
prolonged partial remission of 14 months, and the response is still continuing. Up to 
now, no data from randomized clinical studies have been published addressing the 
question of efficacy of temsirolimus as third-line treatment after failure of tyrosine kinase 
inhibitors. The case presented here implies that temsirolimus could be a viable option for 
patients with metastatic chromophobe renal cell carcinoma. 
 
Case Report 
A 27-year-old female patient developed macrohematuria in January 2004. Imaging showed a large 
right renal mass without metastases. She underwent nephrectomy, and the histology revealed a renal cell 
carcinoma (RCC) of chromophobe type, eosinophilic variant. Maximum tumor diameter was 12 cm, 
with extensive necrosis, grade IV according to Fuhrman’s nuclear grading system. A single hilar lymph 
node was found to be infiltrated, resulting in stage pT2 pN1 cM0. Neither the renal vein nor the adrenal 
gland was infiltrated. 
In August 2007, a routine follow-up ultrasound revealed multiple liver lesions. Fine needle aspiration 
confirmed the diagnosis of liver metastases of chromophobe RCC. A CT scan showed multiple bilateral 
pulmonary as well as diffuse liver metastases. Treatment with sunitinib 50 mg on a 4 weeks on/2 weeks 
off schedule was initiated, resulting in stable disease. However, the doses had to be reduced due to grade 
3 palmar and plantar toxicity. 
At the end of March 2009, after 20 months of treatment, an MRI showed progressive liver disease as 
well as local recurrence and mesenteric lymph node metastases. Sorafenib was started as a second-line 
treatment. The initial dose of 800 mg daily had to be reduced to 600 mg due to a hematologic toxicity.  
Case Rep Oncol 2011;4:16–18 
DOI: 10.1159/000323804 
Published online: 
January 15, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
17
No objective response was achieved, and the performance status decreased from 0 to 2, with a 7-kg 
weight loss. 
After 5 months of sorafenib therapy, an MRI revealed further progression at all sites (fig. 1; online 
suppl. video 1; see www.karger.com/doi/10.1159/000323804). At the end of August 2009, temsirolimus 
was started as a third-line treatment at a dose of 25 mg intravenously every week. In November 2009, 
disease stabilization was observed on CT. In February 2009, a further MRI showed a partial remission 
according to the RECIST criteria. Clinically, the patient had improved considerably (PS 0), and formerly 
elevated laboratory values normalized (LDH from 1,400 U/l, alkaline phosphatase from 142 U/l, γGT 
from 168 U/l). 
In July 2010, an impressive partial remission was documented by MRI (fig. 2; online suppl. video 2). 
Currently, the patient continues on weekly temsirolimus, is working full time, and is in excellent 
physical condition without experiencing any side effects. 
Discussion 
This clinical observation of an impressive response to third-line temsirolimus in a case 
of chromophobe metastatic RCC leads us to raise the following questions: first, should the 
current practice of sequential therapy be revisited? Especially in chromophobe metastatic 
RCC, mTOR inhibition may be considered earlier. In this patient, the treatment choice 
was dictated by availability. Today, everolimus is the standard in second-line treatment 
[1], while temsirolimus is approved only for first-line treatment [2]. Thus, temsirolimus 
in later lines is still considered experimental. 
Second, are all mTOR inhibitors equal in terms of efficacy? Would this patient have 
responded equally well to everolimus? This question should be addressed by head-to-head 
comparisons of mTOR inhibitors. 
Since 2006, six molecular targeted agents have been approved for the treatment of RCC 
(sunitinib, sorafenib, bevacizumab/interferon, temsirolimus, everolimus, and pazopanib). 
Currently, sequencing of these agents is based mainly on prognostic risk scores. Maybe 
more emphasis should be placed on the biology of RCC as reflected in its histology. Rare 
subtypes like chromophobe RCC or sarcomatoid dedifferentiated RCC may have to be 
considered separately. Current strategies are based on results obtained in the context of 
clear cell-type RCC. Separate trials for rare histologies seem unfeasible and are unlikely to 
be performed. For these cases, clinical observations are an important part for advancing 
therapeutic insight. 
Currently, the ‘START’ trial [3] is studying temsirolimus as first-line and second-line 
treatment. Patients in this trial are stratified by histological subtype, and the results may 
also answer the question raised by our observation: is chromophobe RCC particularly 
sensitive to mTOR inhibition? 
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Fig. 1. MRI after sunitinib and sorafenib failure. 
 
 
 
Fig. 2. Partial remission after 9 months on temsirolimus. 
 
References 
1  Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, 
Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, 
Moore L, Motzer RJ, Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal-cell 
carcinoma. N Engl J Med 2007;356:2271–2281. 
2  Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, 
randomised, placebo-controlled phase III trial. Lancet 2008;372:449–456. 
3  START ‘Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy’. ClinicalTrials.gov Identifier: 
NCT01217931. 